The Burkitt-like lymphomas

A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

Rita M. Braziel, Daniel A. Arber, Marilyn L. Slovak, Margaret L. Gulley, Catherine S Perry, Carl Kjeldsberg, Joseph Unger, Thomas P Miller, Raymond Tubbs, Catherine Leith, Richard I. Fisher, Thomas M. Grogan

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

The Revised European-American Lymphoma classification gives Burkitt-like lymphoma (BLL) provisional status, leaving unresolved the differential diagnosis with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). This study compared the biologic features of adult BLL and DLBCL. The phenotypic distinction between BLL and DLBCL was determined by immunohistochemical staining of frozen tissue from 13 patients with BLL and 55 patients with DLBCL by using an extensive antibody panel including Ki-67, CD10, CD11a/lymphocyte function-associated antigen 1α (LFA-1α), CD18/LFA-1β, CD58/LFA-3, and CD54/intercellular adhesion molecule, CD8 for tumor-infiltrating cytotoxic T cells (T-TILs), CD44 homing receptor, and p53 and Bcl-2 oncogenic proteins. Compared with DLBCL, BLL had a higher proliferative rate (mean Ki-67, 88% versus 53%), greater expression of CD10 and p53 antigens, and decreased expression of Bcl-2. BLL cases had a consistent absence of one or more cell adhesion molecules (92% versus 27%), low T-TIL numbers, and absence of CD44 homing receptor (92% versus 14%). The t(8;14) translocation was identified in 80% of BLL cases, but no patients with BLL had the t(14;18) translocation. In a 10-year analysis, median survival of patients with BLL was 1.2 years, and that of patients with DLBCL was 2.5 years. Although the proportion of patients cured was similar in the 2 groups, BLL patients had an increased risk of early death. We conclude that BLL can be recognized by its combined morphologic and phenotypic features and that it represents a high-grade lymphoma much closer to BL than DLBCL. Retention of the BLL category or inclusion of BLL as a variant of BL is biologically and clinically more appropriate than absorbing the category of BLL into DLBCL.

Original languageEnglish (US)
Pages (from-to)3713-3720
Number of pages8
JournalBlood
Volume97
Issue number12
DOIs
StatePublished - Jun 15 2001

Fingerprint

Lymphocyte Function-Associated Antigen-1
Oncology
Burkitt Lymphoma
Cell Adhesion Molecules
CD58 Antigens
Tumor Suppressor Protein p53
Neprilysin
T-cells
Lymphoma, Large B-Cell, Diffuse
Tumors
Cells
Tissue
Antibodies
Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Braziel, R. M., Arber, D. A., Slovak, M. L., Gulley, M. L., Perry, C. S., Kjeldsberg, C., ... Grogan, T. M. (2001). The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood, 97(12), 3713-3720. https://doi.org/10.1182/blood.V97.12.3713

The Burkitt-like lymphomas : A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. / Braziel, Rita M.; Arber, Daniel A.; Slovak, Marilyn L.; Gulley, Margaret L.; Perry, Catherine S; Kjeldsberg, Carl; Unger, Joseph; Miller, Thomas P; Tubbs, Raymond; Leith, Catherine; Fisher, Richard I.; Grogan, Thomas M.

In: Blood, Vol. 97, No. 12, 15.06.2001, p. 3713-3720.

Research output: Contribution to journalArticle

Braziel, RM, Arber, DA, Slovak, ML, Gulley, ML, Perry, CS, Kjeldsberg, C, Unger, J, Miller, TP, Tubbs, R, Leith, C, Fisher, RI & Grogan, TM 2001, 'The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features', Blood, vol. 97, no. 12, pp. 3713-3720. https://doi.org/10.1182/blood.V97.12.3713
Braziel, Rita M. ; Arber, Daniel A. ; Slovak, Marilyn L. ; Gulley, Margaret L. ; Perry, Catherine S ; Kjeldsberg, Carl ; Unger, Joseph ; Miller, Thomas P ; Tubbs, Raymond ; Leith, Catherine ; Fisher, Richard I. ; Grogan, Thomas M. / The Burkitt-like lymphomas : A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. In: Blood. 2001 ; Vol. 97, No. 12. pp. 3713-3720.
@article{22f5fc8880ac48ac85e1f61c69b61507,
title = "The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features",
abstract = "The Revised European-American Lymphoma classification gives Burkitt-like lymphoma (BLL) provisional status, leaving unresolved the differential diagnosis with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). This study compared the biologic features of adult BLL and DLBCL. The phenotypic distinction between BLL and DLBCL was determined by immunohistochemical staining of frozen tissue from 13 patients with BLL and 55 patients with DLBCL by using an extensive antibody panel including Ki-67, CD10, CD11a/lymphocyte function-associated antigen 1α (LFA-1α), CD18/LFA-1β, CD58/LFA-3, and CD54/intercellular adhesion molecule, CD8 for tumor-infiltrating cytotoxic T cells (T-TILs), CD44 homing receptor, and p53 and Bcl-2 oncogenic proteins. Compared with DLBCL, BLL had a higher proliferative rate (mean Ki-67, 88{\%} versus 53{\%}), greater expression of CD10 and p53 antigens, and decreased expression of Bcl-2. BLL cases had a consistent absence of one or more cell adhesion molecules (92{\%} versus 27{\%}), low T-TIL numbers, and absence of CD44 homing receptor (92{\%} versus 14{\%}). The t(8;14) translocation was identified in 80{\%} of BLL cases, but no patients with BLL had the t(14;18) translocation. In a 10-year analysis, median survival of patients with BLL was 1.2 years, and that of patients with DLBCL was 2.5 years. Although the proportion of patients cured was similar in the 2 groups, BLL patients had an increased risk of early death. We conclude that BLL can be recognized by its combined morphologic and phenotypic features and that it represents a high-grade lymphoma much closer to BL than DLBCL. Retention of the BLL category or inclusion of BLL as a variant of BL is biologically and clinically more appropriate than absorbing the category of BLL into DLBCL.",
author = "Braziel, {Rita M.} and Arber, {Daniel A.} and Slovak, {Marilyn L.} and Gulley, {Margaret L.} and Perry, {Catherine S} and Carl Kjeldsberg and Joseph Unger and Miller, {Thomas P} and Raymond Tubbs and Catherine Leith and Fisher, {Richard I.} and Grogan, {Thomas M.}",
year = "2001",
month = "6",
day = "15",
doi = "10.1182/blood.V97.12.3713",
language = "English (US)",
volume = "97",
pages = "3713--3720",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - The Burkitt-like lymphomas

T2 - A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

AU - Braziel, Rita M.

AU - Arber, Daniel A.

AU - Slovak, Marilyn L.

AU - Gulley, Margaret L.

AU - Perry, Catherine S

AU - Kjeldsberg, Carl

AU - Unger, Joseph

AU - Miller, Thomas P

AU - Tubbs, Raymond

AU - Leith, Catherine

AU - Fisher, Richard I.

AU - Grogan, Thomas M.

PY - 2001/6/15

Y1 - 2001/6/15

N2 - The Revised European-American Lymphoma classification gives Burkitt-like lymphoma (BLL) provisional status, leaving unresolved the differential diagnosis with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). This study compared the biologic features of adult BLL and DLBCL. The phenotypic distinction between BLL and DLBCL was determined by immunohistochemical staining of frozen tissue from 13 patients with BLL and 55 patients with DLBCL by using an extensive antibody panel including Ki-67, CD10, CD11a/lymphocyte function-associated antigen 1α (LFA-1α), CD18/LFA-1β, CD58/LFA-3, and CD54/intercellular adhesion molecule, CD8 for tumor-infiltrating cytotoxic T cells (T-TILs), CD44 homing receptor, and p53 and Bcl-2 oncogenic proteins. Compared with DLBCL, BLL had a higher proliferative rate (mean Ki-67, 88% versus 53%), greater expression of CD10 and p53 antigens, and decreased expression of Bcl-2. BLL cases had a consistent absence of one or more cell adhesion molecules (92% versus 27%), low T-TIL numbers, and absence of CD44 homing receptor (92% versus 14%). The t(8;14) translocation was identified in 80% of BLL cases, but no patients with BLL had the t(14;18) translocation. In a 10-year analysis, median survival of patients with BLL was 1.2 years, and that of patients with DLBCL was 2.5 years. Although the proportion of patients cured was similar in the 2 groups, BLL patients had an increased risk of early death. We conclude that BLL can be recognized by its combined morphologic and phenotypic features and that it represents a high-grade lymphoma much closer to BL than DLBCL. Retention of the BLL category or inclusion of BLL as a variant of BL is biologically and clinically more appropriate than absorbing the category of BLL into DLBCL.

AB - The Revised European-American Lymphoma classification gives Burkitt-like lymphoma (BLL) provisional status, leaving unresolved the differential diagnosis with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). This study compared the biologic features of adult BLL and DLBCL. The phenotypic distinction between BLL and DLBCL was determined by immunohistochemical staining of frozen tissue from 13 patients with BLL and 55 patients with DLBCL by using an extensive antibody panel including Ki-67, CD10, CD11a/lymphocyte function-associated antigen 1α (LFA-1α), CD18/LFA-1β, CD58/LFA-3, and CD54/intercellular adhesion molecule, CD8 for tumor-infiltrating cytotoxic T cells (T-TILs), CD44 homing receptor, and p53 and Bcl-2 oncogenic proteins. Compared with DLBCL, BLL had a higher proliferative rate (mean Ki-67, 88% versus 53%), greater expression of CD10 and p53 antigens, and decreased expression of Bcl-2. BLL cases had a consistent absence of one or more cell adhesion molecules (92% versus 27%), low T-TIL numbers, and absence of CD44 homing receptor (92% versus 14%). The t(8;14) translocation was identified in 80% of BLL cases, but no patients with BLL had the t(14;18) translocation. In a 10-year analysis, median survival of patients with BLL was 1.2 years, and that of patients with DLBCL was 2.5 years. Although the proportion of patients cured was similar in the 2 groups, BLL patients had an increased risk of early death. We conclude that BLL can be recognized by its combined morphologic and phenotypic features and that it represents a high-grade lymphoma much closer to BL than DLBCL. Retention of the BLL category or inclusion of BLL as a variant of BL is biologically and clinically more appropriate than absorbing the category of BLL into DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=0035877997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035877997&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.12.3713

DO - 10.1182/blood.V97.12.3713

M3 - Article

VL - 97

SP - 3713

EP - 3720

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -